Use of corticosteroid sparing systemic immunosuppression for treatment of corticosteroid dependent optic neuritis not associated with demyelinating disease

British Journal of Ophthalmology

Volumn 88, Issue 5, 2004, Pages 673-680

  Myers, T D ^a   Smith, J R ^a   Wertheim, M S ^a   Egan, R A ^a   Shults, W T ^b   Rosenbaum, J T ^a,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b DEVERS EYE INSTITUTE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AGED; ANEMIA; AUTOIMMUNE DISEASE; BODY WEIGHT DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DEMYELINATING DISEASE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HAIR LOSS; HEADACHE; HEMORRHAGIC CYSTITIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MEDICAL RECORD; NAUSEA; OPTIC NERVE DISEASE; PAIN; PARESTHESIA; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SARCOIDOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; VISUAL IMPAIRMENT;

ADRENAL CORTEX HORMONES; ADULT; AGED; DEMYELINATING DISEASES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; OPTIC NEURITIS; RETROSPECTIVE STUDIES;

EID: 1942453417     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2003.028472     Document Type: Review

References (23)

1. Miller NR, Newman NJ, Walsh, eds. Hoyt's Clinical Neuro-ophthalmology 5th ed. Baltimore: Williams and Wilkins, 1997;1:599-648.
2. Optic neuritis study group. The clinical profile of optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol 1991;109:1673-8.
3. Rodriguez M, Silva A, Cross SA, et al. Optic neuritis: a population-based study in Olmstead County, Minnesota. Neurology 1995;45:244-50.
4. Dutton JJ, Burde RM, Klingele TG. Autoimmune retrobulbar optic neuritis. Am J Ophthalmol 1982;94:11-17.
5. Kidd D, Burton B, Plant GT, et al. Chronic relapsing inflammatory optic neuropathy (CRION). Brain 2003;126:276-84.
6. Galindo-Rodriguez G, Anvina-Zubieta JA, Pizarro S, et al. Cyclophosphamide pulse therapy in optic neuritis due to systemic lupus erythematosus: an open trial. Am J Med 1999;106:65-9.
7. Stanbury RM, Graham EM. Systemic corticosteroid therapy-side effects and their management. Br J Ophthalmol 1998;82:704-8.
8. Tamesis RR, Rodriguez A, Christen WG, et al. Systemic drug toxicity trends in immunosuppressive therapy of immune and inflammatory ocular disease. Ophthalmology 1996;103:768-75.
9. Siatkowski RM, Scott IU, Verm AM, et al. Optic neuropathy and chiasmopathy in the diagnosis of systemic lupus erythematosus. J Neuroophthalmol 2001;21:193-8.
10. Frohman LP, Frieman BJ, Wolansky L. Reversible blindness resulting from optic chiasmitis secondary to systemic lupus erythematosus. J Neuroophthalmol 2001;21:18-21.
11. Rosenbaum JT, Simpson J, Neuwelt CM. Successful treatment of optic neuropathy in association with systemic lupus erythematosus using intravenous cyclophosphamide. Br J Ophthalmol 1997;81:130-2.
12. Purvin VA, Chioran G. Recurrent neuroretinitis. Arch Ophthalmol 1994;112:365-71.
13. Bielory L, Frohman LP. Low-dose cyclosporine therapy of granulomatous optic neuropathy and orbitopathy. Ophthalmology 1991;98:1732-6.
14. Gelwan MJ, Kellen RI, Burde RM, et al. Sarcoidosis of the anterior visual pathway: successes and failures. J Neural Neurosurg Psychiatry 1988;51:1473-80.
15. Gressel MG, Tomsak RL. Recurrent bilateral optic neuropathy in mixed connective tissue disease. J Clin Neuroophthalmol 1983;3:101-4.
16. Kupersmith MJ, Burde RM, Warren FA, et al. Autoimmune optic neuropathy: evaluation and treatment. J Neurol Neurosurg Psychiatry 1988;51:1381-6.
17. Maust HA, Foroozan R, Sergott RC, et al. Use of methotrexate in sarcoid-associated optic neuropathy. Ophthalmology 2003;110:559-63.
18. Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000;130:492-513.
19. Takada K, Illei GG, Boumpas DT. Cydophosphamide for the treatment of systemic lupus erythematosus. Lupus 2001;10:154-61.
20. van der Laken CJ, Lems WF, van Soesbergen RM, et al. Paraplegia in a patient receiving anti-tumor necrosis factor therapy for rheumatoid arthritis: comment on the article by Mohan et al. Arthritis Rheum 2003;48:269-70.
21. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9.
22. Favalli EG, Sinigaglia L, Varenna M, et al. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus 2002;11:753-5.
23. Debandt M, Vittecoq O, Descamps V, et al. Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol 2003;22:56-61.